Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer.
暂无分享,去创建一个
R. Herbst | E. Rasmussen | L. Paz-Ares | J. Bendell | D. Ferry | H. Arkenau | G. Mi | N. Penel | I. Chau | M. Wermke | H. Bischoff | B. Chao | Hong Wang | A. Soriano | R. Santana-Davila | E. Arrowsmith
[1] Robert W. Hsieh,et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). , 2020 .
[2] A. Osipov,et al. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape , 2019, Journal of Immunotherapy for Cancer.
[3] T. Schlange,et al. Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC , 2019, Cells.
[4] R. Herbst,et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. , 2019, The Lancet. Oncology.
[5] David L Rimm,et al. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. , 2019, JAMA oncology.
[6] Jianying Zhou,et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.
[7] M. Kudo,et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[8] H. Wada,et al. Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment , 2018, Journal of Immunotherapy for Cancer.
[9] G. Hampton,et al. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1) , 2018, Proceedings of the National Academy of Sciences.
[10] Mengzhong Liu,et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer , 2018, Medicine.
[11] R. Herbst,et al. Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF) , 2018, The oncologist.
[12] S. Culine,et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial , 2017, The Lancet.
[13] Linghong Guo,et al. Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials , 2017, Drug design, development and therapy.
[14] J. Mackey,et al. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] J. Lunceford,et al. IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.
[16] M. Ahn,et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] Jason B. Williams,et al. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. , 2017, Advances in experimental medicine and biology.
[18] J. Luke,et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma , 2016, Proceedings of the National Academy of Sciences.
[19] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[20] E. Van Cutsem,et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. , 2015, The Lancet. Oncology.
[21] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[22] Naotoshi Sugimoto,et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[23] Andreas Sashegyi,et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial , 2014, The Lancet.
[24] C. Fuchs,et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.
[25] E. Tartour,et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. , 2013, Cancer research.
[26] Paul C. Boutros,et al. NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data , 2012, Bioinform..
[27] B. Rini,et al. Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients , 2008, Clinical Cancer Research.
[28] Quynh-Thu Le,et al. Non-small cell lung cancer: Clinical practice guidelines in oncology , 2006 .